BioInteractions Unveils Surface-Active Systems, Redefining Medical Device Coatings  

Published: 26 Sep 2025

Author: Precedence Research

Share :

BioInteractions, a leader in the field of advanced biocompatible solutions, has introduced Surface-Active Systems (SAS). A new class of zero-leached coating technology that offers to revolutionise the work of the implant, protect the health outcomes of the patient, and make the healthcare delivery in the world even stronger. These novel surfaces represent a significant step forward in addressing one of the most significant issues plaguing medical implants. The prevention of infections, thrombosis, and the prolongation of implant life without the risks associated with systemic drug treatments.

It is released at a strategic point at a time when the world is on a rampage concerning minimally invasive and long-term implantable devices. Hospital-acquired infections and thrombosis are among the major triggers of medical equipment failure and patient complications. The SAS platform of BioInteractions provides a permanent, location-specific defense mechanism on the device's surface. With durable antimicrobial and antithrombogenic protection, SAS will be able to reduce hospital readmissions, decrease interventions, and alleviate pressure on healthcare systems across the globe.

Surface-active systems comprise two families of products: Surface-Active Therapeutics (SAT) and Surface-Active Materials (SAM), which are tailored to specific clinical and performance requirements. SAT incorporates the breakthrough technologies such as AstutePlus Antithrombogenic and TridAntz Antimicrobial, which provide sustained therapeutic performance without the excretion of active compounds. These treatments do not have to be removed regularly because, unlike conventional drug-eluting coatings. They have the ability to remain permanently active on the medical device surface, continuously protecting it against bloodstream infections and fibrin sheath formation, and clot-related complications. Furthermore, the launch of SAS is likely to transform the medical device coatings market, which has been used for drug-eluting or passive technologies. 

Commenting on the launch, Arjun Luthra, Commercial Director at BioInteractions, said:

“Surface-Active Systems represent a paradigm shift in the way medical device coatings are designed and applied. By combining durability, zero-leaching functionality, and permanent therapeutic performance, we are delivering a new benchmark in patient safety and implant performance. This innovation is about more than just materials—it is about redefining how medical devices interact with the human body, and how healthcare systems can achieve better outcomes with fewer risks.”